At the time our study was initiated (August 2020), there were limited published trial data for chemotherapy‐free regimens combining immunotherapy with anti‐angiogenic therapy specifically for EGFR TKI‐resistant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.